MCM
NVO

Manchester Capital Management’s Novo Nordisk NVO Stock Holding History

Manchester Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Sell
6,510
-5,101
-44% -$219K 0.04% 217
2026
Q1 		$427K Buy
11,611
+6,697
+136% +$317K 0.06% 184
2025
Q4 		$250K Sell
4,914
-2,271
-32% -$116K 0.03% 245
2025
Q3 		$399K Buy
7,185
+1,637
+30% +$95.8K 0.05% 228
2025
Q2 		$383K Buy
5,548
+98
+2% +$6.67K 0.05% 253
2025
Q1 		$378K Sell
5,450
-1
-0% -$83 0.05% 247
2024
Q4 		$469K Sell
5,451
-3,260
-37% -$353K 0.05% 207
2024
Q3 		$1.04M Sell
8,711
-3,262
-27% -$435K 0.12% 115
2024
Q2 		$1.71M Hold
11,973
– – 0.21% 68
2024
Q1 		$1.54M Buy
11,973
+4,528
+61% +$539K 0.19% 80
2023
Q4 		$770K Buy
7,445
+1,759
+31% +$174K 0.1% 124
2023
Q3 		$517K Buy
5,686
+5,414
+1,990% +$477K 0.08% 152
2023
Q2 		$22K Hold
272
– – ﹤0.01% 491
2023
Q1 		$21.6K Hold
272
– – ﹤0.01% 492
2022
Q4 		$18.4K Hold
272
– – ﹤0.01% 418
2022
Q3 		$14K Hold
272
– – ﹤0.01% 432
2022
Q2 		$15K Hold
272
– – ﹤0.01% 443
2022
Q1 		$15K Sell
272
-196
-42% -$10.1K ﹤0.01% 497
2021
Q4 		$26K Sell
468
-560
-54% -$30.3K ﹤0.01% 455
2021
Q3 		$49K Sell
1,028
-270
-21% -$13.1K 0.01% 431
2021
Q2 		$54K Buy
1,298
+466
+56% +$18.1K 0.01% 379
2021
Q1 		$28K Hold
832
– – ﹤0.01% 421
2020
Q4 		$29K Buy
+832
New +$28.8K ﹤0.01% 406
2015
Q1 		– Sell
-5,864
Closed -$124K – 762
2014
Q4 		$124K Sell
5,864
-2,930
-33% -$65.4K 0.02% 491
2014
Q3 		$209K Buy
8,794
+720
+9% +$16.6K 0.03% 341
2014
Q2 		$186K Buy
+8,074
New +$178K 0.02% 382
2013
Q4 		– Sell
-2,710
Closed -$46K – 949
2013
Q3 		$46K Hold
2,710
– – 0.01% 617
2013
Q2 		$42K Buy
+2,710
New +$45.1K 0.01% 635

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Manchester Capital Management's NVO Position: Q2 2026 in Review

Manchester Capital Management reduced its Novo Nordisk (NVO) stake by 44% in Q2 2026, selling an estimated $219K and leaving 6,510 shares worth $312K. The position accounts for 0.04% of the portfolio, ranked #217.

Manchester Capital Management first reported a position in NVO in Q2 2013 and has held it in 28 quarters since. The position peaked at $1.71M in Q2 2024. 1,355 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Manchester Capital Management held 6,510 shares of Novo Nordisk worth $312K as of Q2 2026.
  • Manchester Capital Management sold 5,101 Novo Nordisk shares in Q2 2026, an estimated $219K.
  • Novo Nordisk made up 0.04% of Manchester Capital Management's portfolio in Q2 2026, its #217 holding.
  • Manchester Capital Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 28 quarters since.
  • Manchester Capital Management's Novo Nordisk position peaked at $1.71M in Q2 2024.
  • 1,355 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.